Report : Antacid Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Dosage Form (Tablet, Liquid, Others); Drug Class (Proton pump inhibitors, H2 Antagonist, Acid neutralizers); Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) and Geography
Liquid segment of the Antacid Market to Grow at Fastest CAGR during Forecast Period
According to our new market research study on “Antacid Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Dosage Form, Drug Class And Distribution Channel,” the market is expected to reach US$ 11,666.83 million in 2027 from US$ 8,547.97 million in 2019. The market is estimated to grow with a CAGR of 4.0% from 2020-2027. The report highlights trends prevailing in the global Antacid market, and the drivers and restraints pertaining to the market growth.
Based on dosage form, the antacid market is segmented into tablet, liquid, and others. In 2019, the microbial tablet segment held the largest share of the market. The liquid segment is expected to grow at the fastest rate during the forecast period. liquid dosage form is preferred by children and ageing population due to its flavored/palatable taste. Also, presence of major market players such as Procter & Gamble, Pfizer, GSK GROUP and others are offering liquid antacids which is likely to propel the growth of the segment.
The global antacid market growth is mainly attributed to factors such as rising prevalence of healthcare-associated infections and increasing emphasis on food safety. However, limitations of ATP swab tests hinder the market growth.
Sanofi, GlaxoSmithKline plc, Bayer AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Ltd, Boehringer Ingelheim International Gmbh, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc, Reckitt Benckiser Group Plc., and Procter And Gamble are among the leading companies operating in the antacid market.
The report segments global Antacid market as follows:
By Dosage Form
By Drug class
By Distribution Channel